AbbVie and Genmab Report Results of Epcoritamab in P-I/II (EPCORE NHL-1) Trial for the Treatment of R/R Large B-cell Lymphoma
Shots:
- The results from the 1st cohort of the P-I/II (EPCORE NHL-1) trial consist of 2 parts i.e., dose-escalation & expansion part evaluating the safety & preliminary efficacy of epcoritamab (DuoBody-CD3xCD20) in 157 patients with r/r LBCL who received two prior lines of systemic therapy. Epcoritamab is being co-developed by AbbVie & Genmab
- The results showed ORR (63.1%), m-DoR (12mos.) & the mean lines of prior therapy were 3.5, grade 3 CRS (2.5%), and 38.9% received prior treatment with CAR T-cell therapy
- The companies remain committed to evaluating epcoritamab as a monothx. & in combination to treat hematologic malignancies. The therapy is being evaluated in the P-III trial as monothx. for r/r DLBCL
Ref: PR Newswire | Image: AbbVie
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
